监管批准与进展 - FDC Ltd获得美国FDA对毛果芸香碱盐酸盐眼药水USP（1%、2%、4%，15 mL）的ANDA批准 [1] - Bajaj Healthcare获得CDSCO专家委员会正面推荐，可启动Suvorexant片剂（5mg, 10mg, 15mg, 20mg）的三期临床试验，成为印度首家获得该失眠症治疗药物监管许可的公司 [3] - AstraZeneca Pharma India Ltd获得CDSCO许可，可进口并销售Trastuzumab Deruxtecan（品牌名：Enhertu）100mg/5mL冻干粉末 [4] 公司交易与所有权变更 - Apollo Hospitals Enterprise完成收购Apollo Gleneagles PET-CT（AGPCL）50%的股权，共计850万股面值10卢比的股票，使AGPCL成为其全资子公司 [2] - 印度资本市场监管机构SEBI批准IHH Healthcare Berhad对Fortis Healthcare及其子公司Fortis Malar Hospitals发起收购26.1%股权的公开要约，该要约此前已停滞七年 [7] 监管审查与合规问题 - Torrent Pharmaceuticals收到国家药品定价管理局（NPPA）发出的超过6.63亿卢比的需求通知，涉及2016年1月至2018年11月期间五种药物的涉嫌超额收费问题 [5] - 美国FDA在检查Lupin的Pithampur Unit-2工厂后发出包含四项缺陷的Form-483，并将该工厂的检查分类确定为“官方行动指示”（OAI） [6]

The market is sleeping on these stocks, but you don't have to.Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good news is that this often creates opportunities for astute investors to pick up shares of great companies with excellent prospects on the dip.And that's precisely what we have with Novo Nordisk (NVO 1.59%) and Vertex Pharmaceuticals (VRTX -1.40%), two le ...

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.It has developed many medicines over the years; most recently, it has been known for developing its highly successful COVID vaccine Comirnaty. Growth and innovation have enabled the company to become a household name and a leader ...

Two Indian drugmakers have come under regulatory scrutiny after cough syrups made by them were linked to a number of child deaths in Madhya Pradesh and Rajasthan. The central drug regulator has swung into action after finding a toxic contaminant in one of the cough syrups tested. Some states have banned the sale of these drugs. This isn’t the first time cough syrups made in India have been linked to fatalities in children. In recent years, India-made cough syrups have come under global scrutiny—they have be ...

We revisit Sanofi (NASDAQ: SNY ) ( OTCPK:SNYNF ) ( GCVRZ ) after our downgrade in early May 2024, a move that has so far been validated by the market, with the S&P 500 delivering double-digitBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be treated as such. We take no ...

公司投资动态 - 赛诺菲宣布向赛诺菲风险投资基金追加6.25亿美元投资 使该基金总资产超过14亿美元 [1] - 此次投资旨在支持该基金长期专注于生物技术和数字健康领域的初创公司 [2] - 赛诺菲风险投资基金自2012年成立以来 已向全球约70家公司投资超过8亿美元 投资阶段覆盖从早期种子轮到IPO [2] - 该基金通过参与被投公司董事会和协助退出等方式提供支持 [2] 公司业务概况 - 赛诺菲是一家总部位于法国的全球医疗保健公司 [3] - 公司业务包括药品、疫苗和消费者保健产品的研发、开发、生产和营销 [3]

Merck & Co., Inc. (NYSE:MRK) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Courtney Breen from Bernstein reiterated a Hold rating on Merck & Co., Inc. (NYSE:MRK) without disclosing any price target. Merck & Co., Inc. (NYSE:MRK) is set to announce its fiscal third quarter results on October 30. The company posted mixed results during its second quarter of 2025. The company topped Wall Street estimates with an EPS of $2.13, ahead of the consensus by $0.10. However, the revenue of $1 ...

Pfizer Inc. (NYSE:PFE) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Reuters reported that Pfizer Inc. (NYSE:PFE) and President Donald Trump had announced a deal to lower Medicaid drug prices in the US. The company agreed to match its Medicaid prices to those it charges in other developed countries in exchange for tariff relief on its imports. President Trump noted that Pfizer Inc. (NYSE:PFE) will offer its most favoured nation prices on all new drugs launched in the United States ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby po ...

公司核心产品与前景 - 公司GLP-1药物被强调用于糖尿病和减肥 并被认为未来可能应用于高血压、痴呆及酒精中毒等更广泛领域[1] - 公司股票表现因该药物的给药方式欠佳而受到阻碍[1] 公司战略与投资 - 公司计划投资65亿美元以加强其产品管线的生产能力[2] - 公司业务涵盖糖尿病、肥胖症、肿瘤学、免疫学、神经科学及胃肠道疾病等领域药物的开发与销售[2]